CY1122374T1 - Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων - Google Patents
Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειωνInfo
- Publication number
- CY1122374T1 CY1122374T1 CY20191101195T CY191101195T CY1122374T1 CY 1122374 T1 CY1122374 T1 CY 1122374T1 CY 20191101195 T CY20191101195 T CY 20191101195T CY 191101195 T CY191101195 T CY 191101195T CY 1122374 T1 CY1122374 T1 CY 1122374T1
- Authority
- CY
- Cyprus
- Prior art keywords
- biotin
- neuropathies
- demyelinotic
- therapeutic treatment
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Ceramics (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Farming Of Fish And Shellfish (AREA)
Abstract
Η εφεύρεση σχετίζεται με τη χρήση της βιοτίνης για την θεραπευτική αντιμετώπιση της Αμυοτροφικής Πλευρικής Σκλήρυνσης, καθώς και απομυελινωτικών περιφερικών νευροπαθειών και της Οπτικής Νευρομυελίτιδας (ΝΜΟ).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (en) | 2015-03-26 | 2015-03-26 | Biotin for treating Amyotrophic lateral sclerosis |
| PCT/EP2016/056696 WO2016151132A1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122374T1 true CY1122374T1 (el) | 2021-01-27 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101195T CY1122374T1 (el) | 2015-03-26 | 2019-11-13 | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (el) |
| EP (2) | EP3072513A1 (el) |
| JP (1) | JP6752874B2 (el) |
| KR (1) | KR20170131543A (el) |
| CN (2) | CN111973592A (el) |
| AU (1) | AU2016238759B2 (el) |
| BR (1) | BR112017020408A2 (el) |
| CA (1) | CA2980660A1 (el) |
| CY (1) | CY1122374T1 (el) |
| DK (1) | DK3273957T3 (el) |
| EA (1) | EA034394B1 (el) |
| ES (1) | ES2748354T3 (el) |
| HR (1) | HRP20191491T1 (el) |
| HU (1) | HUE046116T2 (el) |
| IL (1) | IL254619B (el) |
| LT (1) | LT3273957T (el) |
| MA (1) | MA41809B1 (el) |
| ME (1) | ME03567B (el) |
| PL (1) | PL3273957T3 (el) |
| PT (1) | PT3273957T (el) |
| RS (1) | RS59149B1 (el) |
| SI (1) | SI3273957T1 (el) |
| WO (1) | WO2016151132A1 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| CA3121634A1 (en) * | 2018-12-11 | 2020-06-18 | Myospots Australia Pty Ltd | Adhesive pad |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| RS20050255A (en) | 2002-09-27 | 2007-08-03 | Biogen Idec Ma Inc., | Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-betha |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| BR112012015084A2 (pt) | 2009-12-23 | 2017-03-07 | Lupin Ltd | composição farmacêutica de liberação lenta de iloperidone |
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| CN103702682A (zh) * | 2011-04-21 | 2014-04-02 | 科罗拉多州立大学董事会法人团体 | 治疗视神经脊髓炎的组合物和方法 |
| US10272082B2 (en) * | 2011-07-13 | 2019-04-30 | Cytokinetics, Inc. | Combination ALS therapy |
| CA2910717C (en) | 2013-04-29 | 2021-01-26 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/en not_active Ceased
-
2016
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/me unknown
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko unknown
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/en active Active
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 CA CA2980660A patent/CA2980660A1/en not_active Abandoned
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/en active Application Filing
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-08-19 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3273957A1 (en) | 2018-01-31 |
| NZ735528A (en) | 2021-09-24 |
| RS59149B1 (sr) | 2019-09-30 |
| LT3273957T (lt) | 2019-11-11 |
| US20180125825A1 (en) | 2018-05-10 |
| EP3273957B1 (en) | 2019-08-14 |
| CN111973592A (zh) | 2020-11-24 |
| HRP20191491T1 (hr) | 2019-11-15 |
| ME03567B (me) | 2020-07-20 |
| WO2016151132A1 (en) | 2016-09-29 |
| CN107405335A (zh) | 2017-11-28 |
| US10357480B2 (en) | 2019-07-23 |
| AU2016238759A1 (en) | 2017-10-05 |
| JP2018512451A (ja) | 2018-05-17 |
| PL3273957T3 (pl) | 2020-01-31 |
| PT3273957T (pt) | 2019-09-18 |
| SI3273957T1 (sl) | 2019-11-29 |
| ES2748354T3 (es) | 2020-03-16 |
| BR112017020408A2 (pt) | 2018-06-05 |
| HUE046116T2 (hu) | 2020-02-28 |
| MA41809B1 (fr) | 2019-12-31 |
| IL254619A0 (en) | 2017-11-30 |
| EA201792124A1 (ru) | 2018-04-30 |
| DK3273957T3 (da) | 2019-11-11 |
| MA41809A (fr) | 2018-01-30 |
| US20190314342A1 (en) | 2019-10-17 |
| JP6752874B2 (ja) | 2020-09-09 |
| AU2016238759B2 (en) | 2020-08-06 |
| KR20170131543A (ko) | 2017-11-29 |
| CA2980660A1 (en) | 2016-09-29 |
| EP3072513A1 (en) | 2016-09-28 |
| IL254619B (en) | 2020-03-31 |
| EA034394B1 (ru) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1121182T1 (el) | Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit | |
| CY1123417T1 (el) | Παραγωγα τετρα�δροϊσοκινολινης | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| EA201890204A1 (ru) | Антибактериальные соединения | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CY1122374T1 (el) | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| EA202090683A3 (ru) | Способы и композиции для лечения рака | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| BR112018002382A8 (pt) | Novos anticorpos anti-gvpi humano e usos dos mesmos | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| CY1125031T1 (el) | Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης | |
| BR112018012116A2 (pt) | terapia intravesical para câncer de bexiga | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose |